Evidence map›Paper›PMID 24927725›Full record

ArticleFamily practice2014

Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting.

Orit Cohen Castel, Lital Keinan-Boker, Orna Geyer, Uzi Milman, Khaled Karkabi

Open access · hybridAbstract read
In one paragraph

Article in Family practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Access to and Experiences with, e-Health Technology Among Glaucoma Patients and Their Relationship with Medication Adherence.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2018
    Article
  13. Article
  14. Drop instillation and glaucoma.Current opinion in ophthalmology · 2018
    Review
  15. Glaucoma therapy: preservative-free for all?Clinical ophthalmology (Auckland, N.Z.) · 2018
    Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Orit Cohen CastelDivision of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, hforitco@gmail.com.
Lital Keinan-BokerFaculty of Social Welfare and Health Sciences, School of Public Health, University of Haifa, Haifa.
Orna GeyerDepartment of Ophthalmology, Carmel Medical Center, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa and.
Uzi MilmanDivision of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Department of Family Medicine and Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District, Haifa, Israel.
Khaled KarkabiDivision of Family Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Department of Family Medicine and.
Technion – Israel Institute of Technology · ILCarmel Medical Center · ILUniversity of Haifa · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary open-angle glaucoma is a leading cause of irreversible blindness.

objectivesTo identify factors associated with adherence to glaucoma pharmacotherapy in the primary care setting, focusing on physicians' role.

methodsPatients were recruited from primary care clinics and telephone-interviewed using a structured questionnaire that addressed patient-, medication-, environment- and physicians-related factors. Patients' data on pharmacy claims were retrieved to calculate the medication possession ratio for measuring adherence.

resultsSeven hundred thirty-eight glaucoma patients were interviewed. The multivariate analysis identified eight variables that were associated independently with adherence. Barriers to adherence were found to be low income, believing that 'It makes no difference to my vision whether I take the drops or not' and relying on someone else for drop instillation (exp(B) = 1.91, P = 0.002; exp(B) = 2.61, P < 0.0001; exp(B) = 2.17, P = 0.001, respectively). Older age, having a glaucoma patient among close acquaintances, taking a higher number of drops per day, taking a prostaglandin drug and reporting that the ophthalmologist had discussed the importance of taking eye drops as prescribed, were found to promote adherence (exp(B) = 0.96, P < 0.0001; exp(B) = 0.54, P = 0.014; exp(B) = 0.81, P = 0.001; exp(B) = 0.37, P < 0.0001; exp(B) = 0.60, P = 0.034, respectively). No association was found between the patient's relationship with the family physician and adherence to glaucoma treatment.

conclusionAdherence to glaucoma pharmacotherapy is associated with patient-related, medication-related, physician-related and environmental factors. Ophthalmologists have a significant role in promoting adherence. However, the potential role of family physicians is unfulfilled and unrecognized.

Indexed as

Medication AdherencePhysician's RolePrimary Health CareAgedAged, 80 and overAntihypertensive AgentsCross-Sectional StudiesFemaleGlaucomaHumansIsraelMaleOphthalmologyPhysicians, FamilySurveys and QuestionnairesAntihypertensive AgentsDoctor–patient relationshipfamily physiciansglaucomapatient adherenceprimary care.

Identifiers

PMID24927725
PMCPMC4106405
OpenAlexW2140279115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.